The metabolic fate of the anti-HIV active drug carrier succinylated human serum albumin after intravenous administration in rats

Journal of Drug Targeting

Volumn 9, Issue 2, 2001, Pages 95-109

  Swart, P J ^a   Kuipers, M E ^a   Smit, C ^a   Beljaars, L ^a   Ter Wiel, J ^a   Meijer, D K F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Drug targeting; HIV 1; Metabolism; Pharmacokinetics; Polyanion; Succinylated albumin

Indexed keywords

AMINO ACID; AMMONIA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBON 14; CARBOXYL GROUP; DIAZEPAM; DRUG CARRIER; HUMAN SERUM ALBUMIN; HYPNORM; LYSINE; SUCCINIC ANHYDRIDE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TIME;

EID: 0034903136     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611860108997921     Document Type: Article

References (29)

1. Molecular mechanisms of the adsorption of a model protein (human serum albumin) on poly (methylidene malonate 2.1.2) nanoparticles
2. How Human Immunodeficiency Virus Enters Cells: Implications for Pathogenesis
3. Pharmacokinetics, Toxicity, and Activity of Intravenous Dextran Sulfate in Human Immunodeficiency Virus Infection
4. The Amino-Terminal Peptide of HIV-1 Gp41 Interacts with Human Serum Albumin
5. Potent inhibition of replication of primary HIV-1 isolates by negatively charged human serum albumins
6. Glycosyl receptors in macrophage subpopulations of rat spleen and lymph node. A comparative study using neoglycoproteins and monoclonal antibodies ED1, ED2 and ED3
7. Potent In Vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins
8. Pharmacokinetic analysis and cellular distribution of the anti-HIV compound succinylated human serum albumin (Suc-HSA) in vivo and in the isolated perfused rat liver
9. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity
10. Optimization of the reaction conditions for the synthesis of Neoglycoprotein-AZT-monophosphate conjugates
11. Mechanism of anti-HIV activity of negatively charged albumins: Biomolecular interaction with the HIV-1 envelope protein gp120
12. Pharmacokinetics and anti-HIV-1 efficacy of negatively charged human serum albumins in mice
13. Anti-HIV-1 activity of combinations and covalent conjugates of negatively charged human serum albumins (NCAs) and AZT
14. Mechanism of anti-HIV activity of succinylated human serum albumin
15. Retroendocytosis of neoglycoproteins in hepatocytes and endothelial liver cells. Effect of substitution density and charge
16. Hepatobiliary disposition and targeting of drugs and genes
17. Collection of metabolites in bile and urine from the rat
18. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring
19. Influence of taurocholate on hepatic clearance and biliary excretion of asialo intestinal alkaline phosphatase in the rat in vivo and in isolated perfused rat liver
20. A note on confidence intervals with extended least squares parameter estimates
21. A method for frequent sampling of blood and continuous infusion of fluids without disturbing the animal
22. Negatively-charged albumins: A novel class of polyanionic proteins with a potent anti-HIV activity
23. Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA
24. Antiviral effects of milk proteins: Acylation results in polyanionic compounds with potent activity against human immunodeficiency virus type 1 and 2 in vitro
25. Pharmacokinetics of succinylated serum albumin in wistar rats and cynomolgus monkeys: Implications for dosage regimens in the therapy of HIV infection
26. Tolerance and anti-HIV efficacy of negatively charged albumins in rats, monkeys and HIV-infected mice
27. Homing of negatively charged albumins to the lymphatic system: General implications for drug targeting to peripheral tissues and viral reservoirs
28. Charge modification of plasma and milk proteins results in antiviral active compounds
29. Rapid release of galactose-terminated ligands after endocytosis by hepatic parenchymal cells. Evidence for a role of carbohydrate structure in the release of internalized ligand from receptor